Show simple item record

dc.contributor.authorHalwani, A. S.
dc.contributor.authorPanizo, C.
dc.contributor.authorIsufi, I.
dc.contributor.authorHerrera, A. F.
dc.contributor.authorOkada, C. Y.
dc.contributor.authorCull, E. H.
dc.contributor.authorKis, B.
dc.contributor.authorChaves, J. M.
dc.contributor.authorBartlett, N. L.
dc.contributor.authorAi, W.
dc.contributor.authorde la Cruz-Merino, L.
dc.contributor.authorBryan, L. J.
dc.contributor.authorHouot, R.
dc.contributor.authorLinton, Kim M
dc.contributor.authorBriones, J.
dc.contributor.authorChau, I.
dc.contributor.authorvon Keudell, G. R.
dc.contributor.authorLu, H.
dc.contributor.authorYakovich, A.
dc.contributor.authorChen, M.
dc.contributor.authorMeulen, J. H. T.
dc.contributor.authorYurasov, S.
dc.contributor.authorHsu, F. J.
dc.contributor.authorFlowers, C. R.
dc.date.accessioned2022-01-11T12:00:07Z
dc.date.available2022-01-11T12:00:07Z
dc.date.issued2021en
dc.identifier.citationHalwani AS, Panizo C, Isufi I, Herrera AF, Okada CY, Cull EH, et al. Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma Leukemia & Lymphoma. Informa UK Limited; 2021. p. 1–13.en
dc.identifier.pmid34865586en
dc.identifier.doi10.1080/10428194.2021.2010057en
dc.identifier.urihttp://hdl.handle.net/10541/624957
dc.titlePhase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphomaen
dc.typeArticleen
dc.contributor.departmentDivision of Hematology and Hematologic Malignancies, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USAen
dc.identifier.journalLeukemia and Lymphomaen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record